<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04667624</url>
  </required_header>
  <id_info>
    <org_study_id>HL-LDNT-101</org_study_id>
    <nct_id>NCT04667624</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and PK of LODIENT Tablet 80/2.5mg in Healthy Adult Volunteers</brief_title>
  <official_title>A Randomized, Open Label, Single Dose, 2-sequence, 4-period, Cross-over Phase I Clinical Trial to Compare and Evaluate the Safety and PK After Oral Administration of &quot;LodienT Tablet 80/2.5mg&quot; and &quot;TWYNSTA Tablet 80/5mg&quot; in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanlim Pharm. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanlim Pharm. Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, open label, single dose, 2-sequence, 4-period, cross-over phase I clinical&#xD;
      trial to compare and evaluate the safety and pharmacokinetics after oral administration of&#xD;
      &quot;LodienT tablet 80/2.5mg(telmisartan/s-amlodipine)&quot; and &quot;TWINSTA tablet&#xD;
      80/5mg(telmisartan/amlodipine)&quot; in healthy adult volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Amlodipine is a drug which belongs to calcium channel blockers (CCBs) and is used to treat&#xD;
      hypertension. The molecule contains one chiral carbon atom and exists as a racemic mixture.&#xD;
      As only the S-enantiomer of amlodipine [S-amlodipine] shows the CCB effect and R-amlodipine&#xD;
      is responsible for the development of peripheral edema, purifying S-amlodipine can reduce the&#xD;
      incidences of peripheral edema and other side effects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 29, 2020</start_date>
  <completion_date type="Actual">May 18, 2020</completion_date>
  <primary_completion_date type="Actual">April 28, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCt</measure>
    <time_frame>0(pre-dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 7, 8, 12, 24, 48 and 72hr</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>0(pre-dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 7, 8, 12, 24, 48 and 72hr</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Reference</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TWYNSTA Tablet 80/5mg(Telmisartan/Amlodipine)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LodienT Tablet 80/2.5mg(Telmisartan/S-amlodipine)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Twynsta</intervention_name>
    <description>Manufactured by Boehringer Ingelheim</description>
    <arm_group_label>Reference</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LodineT</intervention_name>
    <description>•Manufactured by Hanlim Pharm. Co., Ltd, Seoul, Korea</description>
    <arm_group_label>Test</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy volunteers aged more than 19 years old&#xD;
&#xD;
          2. Subject does not have congenital or chronic disease and is without pathologic symptom&#xD;
             or finding on medical exam.&#xD;
&#xD;
          3. Subject was determined eligible according to the results of clinical laboratory tests&#xD;
             like serum test, hematologic test, blood chemistry test, urine test etc. and vital&#xD;
             signs, electrocardiography, physical exam etc. performed during the screening exam.&#xD;
&#xD;
          4. 90mmHg≤SBP≤139mmHg and 60mmHg≤DBP≤89mmHg)&#xD;
&#xD;
          5. Body mass index (BMI) of 18-30kg/m2&#xD;
&#xD;
          6. Willing and able to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Administration of other drug than can modulate metabolic enzyme within 1 months prior&#xD;
             to the scrrening day.&#xD;
&#xD;
          2. Volunteers considered not eligible for the clinical trial by the investigator (study&#xD;
             doctor) due to reasons including laboratory test results, ECGs, or vital signs&#xD;
&#xD;
          3. Continued excessive use of alcohol(alcohol&gt;21 cups/day) and severe heavy smoker&#xD;
             (cigarette &gt; 20 cigarettes per day)&#xD;
&#xD;
          4. Administration of other investigational products within 6 months prior to the first&#xD;
             dosing&#xD;
&#xD;
          5. Subject with the following conditions in laboratory test : AST(sGOT) or ALT(sGPT) &gt;&#xD;
             Upper normal limit × 1.5&#xD;
&#xD;
          6. Subject with whole blood donation within 60 days, component blood donation within 14&#xD;
             days, blood donation within 30 days&#xD;
&#xD;
          7. Subject who take a medication that affect to the pharmacokinetics of drug within 10&#xD;
             days&#xD;
&#xD;
          8. Subject with decision of non-participation through investigator's review&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Metro Hospital</name>
      <address>
        <city>Anyang</city>
        <state>Kyung Gi</state>
        <zip>430-720</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 8, 2020</study_first_submitted>
  <study_first_submitted_qc>December 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 16, 2020</study_first_posted>
  <last_update_submitted>December 8, 2020</last_update_submitted>
  <last_update_submitted_qc>December 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan amlodipine combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

